Publications in collaboration with researchers from Sociedad Española de Reumatología (9)

2024

  1. Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry

    Annals of the Rheumatic Diseases, Vol. 83, Núm. 9, pp. 1189-1199

2023

  1. Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study

    RMD open, Vol. 9, Núm. 1

2021

  1. Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients?

    Clinical and Experimental Rheumatology, Vol. 39, Núm. 3, pp. 555-563

2020

  1. Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality

    Lupus, Vol. 29, Núm. 12, pp. 1556-1565

2017

  1. Juvenile- and adult-onset systemic lupus erythematosus: A comparative study in a large cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER)

    Clinical and Experimental Rheumatology, Vol. 35, Núm. 6, pp. 1047-1055

2016

  1. Cut-offs and response criteria for the Hospital Universitario la Princesa Index (HUPI) and their comparison to widely-used indices of disease activity in rheumatoid arthritis

    PLoS ONE, Vol. 11, Núm. 9

  2. Fibromyalgia prevalence and related factors in a large registry of patients with systemic lupus erythematosus

    Clinical and Experimental Rheumatology, Vol. 34, pp. 40-47

2015

  1. Analysis of disease activity and response to treatment in a large Spanish cohort of patients with systemic lupus erythematosus

    Lupus, Vol. 24, Núm. 7, pp. 720-729

  2. Cardiovascular events in systemic lupus erythematosus: A Nationwide Study in Spain from the RELESSER Registry

    Medicine (United States), Vol. 94, Núm. 29